Immunovaccine Elects Marc Mansour, Ph.D. to Board of Directors
16 Décembre 2013 - 2:05PM
Marketwired
Immunovaccine Elects Marc Mansour, Ph.D. to Board of Directors
HALIFAX, NOVA SCOTIA--(Marketwired - Dec 16, 2013) -
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company")
(TSX-VENTURE:IMV), a clinical stage vaccine and immunotherapy
company, today announced the election of Marc Mansour, Ph.D., the
Company's Chief Operating Officer (COO), to its board of directors.
Since joining Immunovaccine in 2001, Dr. Mansour has led the
development of Immunovaccine's DepoVax™ platform and the Company's
lead therapeutic cancer vaccine DPX-Survivac, which is poised for
randomized Phase 2 trials in ovarian cancer and glioblastoma.
Previously serving as Chief Science Officer, he was appointed the
Company's COO in September 2013.
Albert Scardino, Executive Chairman of Immunovaccine,
commented,
"Marc is the architect of our cancer immunotherapy program. This
year he has increasingly become the face of Immunovaccine to the
investment community as he has long been to the scientific
community. His interaction with analysts, bankers and investors in
North America and Europe has raised the profile of the company in
this rapidly developing field of cancer treatment. We're pleased to
welcome him to the board."
Immunovaccine expects three trials to be initiated in 2014 with
its cancer immunotherapies that use a patented oil-based delivery
system. The largest study, a randomized Phase II trial of
DPX-Survivac in ovarian cancer, will be sponsored and conducted by
Canada's NCIC Clinical Trials Group (NCIC CTG). The trial is
expected to begin enrolling the first of its 250 patients in
2014.
Additionally, researchers at the University of Rome have
announced plans to initiate a Phase II trial of DPX-Survivac in
glioblastoma (brain cancer) patients in the first half of 2014. A
third trial, using DPX-0907 to treat breast and ovarian cancer, is
planned for initiation at Busto Arsizio Hospital in Milan.
About Ovarian Cancer
Ovarian cancer accounts for more deaths than any other
gynecologic cancer. Symptoms do not occur until it is in the later
stages of the disease, reducing the chance for successful treatment
and remission. It kills more than 100,000 women annually around the
world. Improved surgical techniques have helped to reduce the rate
of recurrence according to some studies, but the average life
expectancy of newly diagnosed ovarian cancer patients is less than
four years.
About Glioblastoma
Glioblastoma, the most common form of brain cancer, is a
fast-growing tumor type that develops from astrocytes, a type of
glial cell present in the brain. The National Cancer Institute
estimates that more than 23,000 Americans will be diagnosed with
brain and other nervous system tumors in 2013. Glioblastoma
accounts for approximately 15 percent of all brain tumors. The
current standard of care for glioblastoma patients calls for
patients to receive maximum surgical resection combined with
radiation and concomitant and adjuvant temozolomide therapy. Newly
diagnosed glioblastoma patients have a median overall survival of
less than 24 months.
About Immunovaccine
Immunovaccine Inc. develops cancer immunotherapies and
infectious disease vaccines based on the Company's DepoVax™
platform, a patented formulation that provides controlled and
prolonged exposure of antigens and adjuvant to the immune system.
Immunovaccine has advanced two T cell activation therapies for
cancer through Phase I human clinical trials. Lead cancer vaccine
therapy, DPX-Survivac, is expected to enter Phase II clinical
studies in both ovarian cancer and glioblastoma (brain cancer). The
Company is also advancing an infectious disease pipeline including
innovative vaccines for respiratory syncytial virus (RSV) and
anthrax. Connect at www.imvaccine.com
This press release contains forward-looking information
under applicable securities law. All information that addresses
activities or developments that we expect to occur in the future,
including information regarding the use of proceeds of the
financing, is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on
the date the statements are made. However, they should not be
regarded as a representation that any of the plans will be
achieved. Actual results may differ materially from those set forth
in this press release due to risks affecting the company, including
access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Dr. Marc MansourChief Operating OfficerImmunovaccine, Inc.T:
(902) 492-1819E: mmansour@imvaccine.comTim BronsVida Strategic
Partners (media)T: (415) 675-7402E: tbrons@vidasp.com
(TSXV:IMV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
(TSXV:IMV)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024